ライフサイエンスコーパス: visceral leishmaniasis

1 nity are still ambiguous during experimental visceral leishmaniasis.

2 mania donovani, causative agent of the fatal visceral leishmaniasis.

3 protozoa, Leishmania donovani chagasi causes visceral leishmaniasis.

4 r systematic subunit vaccine testing against visceral leishmaniasis.

5 that are used to treat the parasitic disease visceral leishmaniasis.

6 herapeutic design and vaccine strategies for visceral leishmaniasis.

7 it with IL-4, plays a protective role during visceral leishmaniasis.

8 Leishmania donovani, the causative agent of visceral leishmaniasis.

9 on into skin but disseminates to cause fatal visceral leishmaniasis.

10 a live attenuated vaccine candidate against visceral leishmaniasis.

11 evelopment of new therapeutic agents against visceral leishmaniasis.

12 ve agent of the tropical infectious disease, visceral leishmaniasis.

13 mployed a well-defined experimental model of visceral leishmaniasis.

14 pool of sera from Brazilians with documented visceral leishmaniasis.

15 shmania chagasi, the cause of South American visceral leishmaniasis.

16 ing host immunity and liver pathology during visceral leishmaniasis.

17 d vaccinia virus-based vaccine against human visceral leishmaniasis.

18 it causes cutaneous, diffuse cutaneous, and visceral leishmaniasis.

19 ive CD8(+) T cells after vaccination against visceral leishmaniasis.

20 e pathogenesis as well as vaccine studies of visceral leishmaniasis.

21 se reported for subclinical canine and human visceral leishmaniasis.

22 orrelated with the probability of developing visceral leishmaniasis.

23 e immunity to Leishmania chagasi, a cause of visceral leishmaniasis.

24 tion is a risk factor for the development of visceral leishmaniasis.

25 the results of a vaccine trial against human visceral leishmaniasis.

26 of new drug targets and their inhibitors for visceral leishmaniasis.

27 inst parasite challenge in a murine model of visceral leishmaniasis.

28 with the life-threatening disease now called visceral leishmaniasis.

29 We tested this strategy in a murine model of visceral leishmaniasis.

30 ally) represent a major advance for treating visceral leishmaniasis.

31 ognostic utility of rK39 in detecting active visceral leishmaniasis.

32 pproved oral drug for treating cutaneous and visceral leishmaniasis.

33 activated late in the course of experimental visceral leishmaniasis.

34 of this strategy to reduce the incidence of visceral leishmaniasis.

35 l drugs have long been the mainstay to treat visceral leishmaniasis.

36 sized and tested against the murine model of visceral leishmaniasis.

37 perties to enter preclinical development for visceral leishmaniasis.

38 ortisol levels have also been found in human visceral leishmaniasis.

39 stage of infection, causing life-threatening visceral leishmaniasis.

40 manifesting as cutaneous, mucocutaneous, and visceral leishmaniasis.

41 iltefosine for Eastern African children with visceral leishmaniasis.

42 frequently after apparent clinical cure from visceral leishmaniasis.

43 al leishmaniasis (PKDL), clinical sequela of visceral leishmaniasis.

44 ted in cultures recovered from patients with visceral leishmaniasis.

45 No vaccine exists against visceral leishmaniasis.

46 d immunity and subsequent protection against visceral leishmaniasis.

47 parasites, in a Brazilian city endemic with visceral leishmaniasis.

48 ense regulation in the liver in experimental visceral leishmaniasis.

49 ni and L. infantum - cause the fatal disease visceral leishmaniasis.

50 L. donovani, the etiological agent of deadly visceral leishmaniasis.

51 ed 287 individuals, including 77 with active visceral leishmaniasis, 26 with post-kala-azar dermal le

52 Of the patients with active visceral leishmaniasis, 42 (55%) were deemed infectious

53 these events, their role remains elusive in visceral leishmaniasis, a disease associated with macrop

54 plicated in the clinical expression of human visceral leishmaniasis, a disease-exacerbating T helper

55 curring beta-glucan immunomodulator, against visceral leishmaniasis, a fatal parasitic disease.

56 establish models for studying recurrence of visceral leishmaniasis, a growing problem in T cell-defi

57 for controlling and preventing the spread of visceral leishmaniasis, a major public health concern in

58 histosomiasis, onchocerciasis, trachoma, and visceral leishmaniasis, a mean delay of 2-3 years for a

59 The condition manifests either as visceral leishmaniasis, a potentially fatal systemic dis

60 Africa is the world region most affected by visceral leishmaniasis, accounting for 45% of cases glob

61 In experimental visceral leishmaniasis, acquired resistance to intracell

62 Cutaneous and visceral leishmaniasis affect an estimated 1.5 million p

63 nducted a Phase II trial in 30 children with visceral leishmaniasis, aged 4-12 years, to test whether

64 Visceral leishmaniasis, also known on the Indian subcont

65 d, may be the first effective oral agent for visceral leishmaniasis, an intracellular protozoal infec

66 ishmania donovani parasites are the cause of visceral leishmaniasis and are transmitted by bites from

67 IL-17A is present in sera from patients with visceral leishmaniasis and decreases after successful tr

68 ctivation observed in patients with American visceral leishmaniasis and human immunodeficiency virus

69 Leishmania donovani is the dermal sequel of Visceral Leishmaniasis and importantly, is the proposed

70 d key roles in promoting inflammation during visceral leishmaniasis and malaria-two important parasit

71 e findings confirm that patients with active visceral leishmaniasis and patients with post-kala-azar

72 Visceral leishmaniasis and severe forms of cutaneous lei

73 Leishmania chagasi causes visceral leishmaniasis and, to a lesser extent, atypical

74 phatic filariasis, trachoma, onchocerciasis, visceral leishmaniasis, and gambiense sleeping sickness)

75 phatic filariasis, onchocerciasis, trachoma, visceral leishmaniasis, and human African trypanosomiasi

76 ing effects regulate outcome in experimental visceral leishmaniasis, and IL-10R blockade represents a

77 Leishmania donovani, the causative agent of visceral Leishmaniasis, and Leishmania tropica, the caus

78 me and response to treatment of experimental visceral leishmaniasis, and MAb targeting of T-cell cost

79 ania donovani, the main etiological agent of visceral leishmaniasis, and the autophagic machinery of

80 esponses are critical for the progression of visceral leishmaniasis, and the pleiotropic cytokine int

81 may overcome compromised T cell responses in visceral leishmaniasis, and this has an important implic

82 Patients with active visceral leishmaniasis are important reservoirs in the a

83 rotection found in vaccine studies of murine visceral leishmaniasis are significantly lower than for

84 Chagas disease and visceral leishmaniasis are two neglected tropical diseas

85 ng diseases (gambiense sleeping sickness and visceral leishmaniasis) are likely to have fewer cases b

86 of Leishmania donovani, the causal agent of visceral leishmaniasis, are conditionally lethal mutatio

87 eglected tropical diseases aims to eliminate visceral leishmaniasis as a public health problem and to

88 proach in east Africa for the elimination of visceral leishmaniasis as a public health problem.

89 egional approach to achieving elimination of visceral leishmaniasis as a public health problem.

90 The cumulative frequency of visceral leishmaniasis at 2 years did not differ signifi

91 ite burden in a 45-day BALB/c mouse model of visceral leishmaniasis at a dosage of 10 mg/kg/day as de

92 bundant in bone marrows of humans with acute visceral leishmaniasis but not in those of uninfected co

93 in Brazil has been used to control zoonotic visceral leishmaniasis but with little success.

94 s disease with 100% efficacy, and suppresses visceral leishmaniasis by 89% (vs 60% for VNI).

95 ote intracellular infection, including human visceral leishmaniasis, by disabling Th1 cell-type respo

96 -beta inhibits Th1-associated cure of murine visceral leishmaniasis caused by L. chagasi, independent

97 ature of many infectious diseases, including visceral leishmaniasis caused by Leishmania donovani.

98 of IL-10 in susceptibility to cutaneous and visceral leishmaniasis caused by Leishmania major and Le

99 Visceral leishmaniasis caused by the intracellular paras

100 Experimental visceral leishmaniasis, caused by infection of mice with

101 In experimental visceral leishmaniasis, caused by infection with the pro

102 Progressive disease in the hamster model of visceral leishmaniasis, caused by Leishmania donovani, i

103 Visceral leishmaniasis, caused by Leishmania infantum, i

104 eglected tropical diseases by WHO, including visceral leishmaniasis, Chagas disease, strongyloidiasis

105 In visceral leishmaniasis, chemotherapy probably seldom era

106 hough human immunodeficiency virus (HIV) and visceral leishmaniasis coinfection is recognized as a ma

107 ered significant protective immunity against visceral leishmaniasis compared with BCG alone.

108 eishmania donovani, the etiological agent of visceral leishmaniasis, confer polyamine auxotrophy to t

109 Clinical manifestations in canine visceral leishmaniasis (CVL) have not been clearly assoc

110 fluidic platform for the diagnosis of canine visceral leishmaniasis (CVL).

111 ible factor 1 alpha in BALB/c mouse model of visceral leishmaniasis decreased liver and spleen parasi

112 rial splenic aspirates from 27 patients with visceral leishmaniasis during monotherapy with interfero

113 y, transmission competence and the impact of visceral leishmaniasis elimination campaigns.Parasitemia

114 -line treatment in different formulations in visceral leishmaniasis endemic areas of Bihar, India.

115 protozoan parasites, the causative agent of visceral leishmaniasis, establish an infection partly by

116 h receptors potential therapeutic targets in visceral leishmaniasis for engagement (TLR4) or blockade

117 cy of different diagnostic methods in feline visceral leishmaniasis (FVL) experimental model.

118 Consequently, an intradermal murine model of visceral leishmaniasis has been explored.

119 ted Leishmania donovani (LdCen(-/-)) against visceral leishmaniasis has been reported extensively.

120 toxicity and resistance of current drugs in visceral leishmaniasis have been reported.

121 In human patients with active visceral leishmaniasis, high IgG levels are predictive o

122 However, in contrast to its role in human visceral leishmaniasis, IL-10 may not play a key immunos

123 In this model of visceral leishmaniasis, IL-6 appears to act in a suppres

124 of such polarized CD4(+) T cells facilitates visceral leishmaniasis in BALB/c mice in a clear contras

125 077 patients aged >/=14 years with confirmed visceral leishmaniasis in Bihar, eastern India, found th

126 etween IL-2R mutations and susceptibility to visceral leishmaniasis in children infected with Leishma

127 ensis is a primary vector of transmission of visceral leishmaniasis in China.

128 aromomycin (SSG/PM) for treatment of primary visceral leishmaniasis in eastern Africa.

129 rnative for children and adults with primary visceral leishmaniasis in eastern Africa.

130 nvenient, safe, and effective treatments for visceral leishmaniasis in Eastern African children are l

131 g a great perspective as a sensing system of visceral leishmaniasis in endemic regions.

132 Experimental visceral leishmaniasis in genetically susceptible mice i

133 is from dogs with clinical manifestations of visceral leishmaniasis in Governador Valadares, an endem

134 This study is nested within the Predicting Visceral Leishmaniasis in HIV-InfectedPatients (PreLeisH

135 ys using crude antigens for the diagnosis of visceral leishmaniasis in human immunodeficiency virus t

136 hmania donovani, the main causative agent of visceral leishmaniasis in humans, and successfully appli

137 Leishmania donovani, the causative agent of visceral leishmaniasis in humans.

138 ular immunity and provide protection against visceral leishmaniasis in mice.

139 Control of human visceral leishmaniasis in regions where it is endemic is

140 d to reduce relapse of previously controlled visceral leishmaniasis in T cell-deficient hosts.

141 proteins of Lutzomyia longipalpis, vector of visceral leishmaniasis in the Americas.

142 ling framework for analyzing the dynamics of visceral leishmaniasis in the Indian sub-continent (VL),

143 m parasites, responsible for transmission of visceral leishmaniasis in the New World.

144 lebotomus argentipes, an important vector of visceral leishmaniasis in the Old World.

145 ling but scarring cutaneous lesions to fatal visceral leishmaniasis in which parasites disseminate to

146 In experimental visceral leishmaniasis, in which the tissue macrophage i

147 In patients with visceral leishmaniasis, increased levels of circulating

148 with cutaneous, visceral, and post-kala azar visceral leishmaniasis indicated that a majority of indi

149 In experimental visceral leishmaniasis, inhibition of interleukin 10 (IL

150 In experimental visceral leishmaniasis, interleukin (IL)-12 initiates co

151 Visceral leishmaniasis is a deadly illness caused by Lei

152 Visceral leishmaniasis is a life-threatening parasitic d

153 Visceral leishmaniasis is a major cause of morbidity and

154 Visceral leishmaniasis is an infectious parasitic diseas

155 In Brazil, human and canine visceral leishmaniasis is caused by infection with Leish

156 sness of patients for the sand fly vector of visceral leishmaniasis is linked to parasites found in t

157 Visceral leishmaniasis is responsible for up to 30,000 d

158 "Kala-azar" (or Indian Visceral Leishmaniasis) is a vector-borne infectious dis

159 Visceral leishmaniasis (kala-azar, KA) is the most sever

160 unity and pathogen clearance in experimental visceral leishmaniasis (Leishmania donovani) but more se

161 In stark contrast, the causative agent of visceral leishmaniasis, Leishmania donovani, does not pr

162 has been generated from a sand fly vector of visceral leishmaniasis, Lutzomyia longipalpis.

163 from self-healing cutaneous lesions to fatal visceral leishmaniasis, mucosal leishmaniasis and diffus

164 shmania chagasi, the cause of South American visceral leishmaniasis, must survive antimicrobial respo

165 ed on an index patient with thymoma, chronic visceral leishmaniasis, myasthenia gravis, and a marked

166 A database of records of cutaneous and visceral leishmaniasis occurrence was compiled from publ

167 The primary endpoint was clinical visceral leishmaniasis or post-kala-azar dermal leishman

168 ed patients with clinically confirmed active visceral leishmaniasis or post-kala-azar dermal leishman

169 sness to the sandfly vector of patients with visceral leishmaniasis or post-kala-azar dermal leishman

170 oint was the proportion of participants with visceral leishmaniasis or post-kala-azar dermal leishman

171 a group of protozoal diseases that includes visceral leishmaniasis, or Kala Azar.

172 ases, such as invasive fungal infections and visceral leishmaniasis, particularly for patients who ar

173 he relevance of asymptomatic and symptomatic visceral leishmaniasis patients as infection reservoirs.

174 We found that human visceral leishmaniasis patients exhibit elevated serum l

175 hat selection for parasite resistance within visceral leishmaniasis patients who have been exposed to

176 By using sera from Sudanese visceral leishmaniasis patients, we confirmed that the T

177 in sera of both cutaneous-leishmaniasis and visceral-leishmaniasis patients.

178 In South Asia, a regional visceral leishmaniasis programme has dramatically reduce

179 also displayed efficacy in a murine model of visceral leishmaniasis, reducing liver parasitemia by 37

180 ial vaccine candidates against cutaneous and visceral leishmaniasis, respectively.

181 encing of TCTP in an infected mouse model of visceral leishmaniasis showed decreased parasite burden

182 ansmitted helminthiases (STH), trachoma, and visceral leishmaniasis, shows that the impact of this di

183 taneous leishmaniasis and a hamster model of visceral leishmaniasis, soluble antigen induces a leishm

184 The drugs currently used to treat visceral leishmaniasis suffer from toxicity and the emer

185 -HLA-DQA1 HLA class II region contributes to visceral leishmaniasis susceptibility in India and Brazi

186 igher levels in bone marrow of patients with visceral leishmaniasis than in controls.

187 5 mm) had a significantly lower frequency of visceral leishmaniasis than non-responders (27/375 [7.2%

188 New drugs for visceral leishmaniasis that are safe, low cost, and adap

189 , suggesting shared genetic risk factors for visceral leishmaniasis that cross the epidemiological di

190 To achieve and sustain elimination of visceral leishmaniasis, the transmission potential of in

191 ce of kala-azar, a clinical manifestation of visceral leishmaniasis, to below 1 in 10,000 by 2020.

192 has been considered the main determinant of visceral leishmaniasis transmission.

193 lent, faces the highest burden world-wide of visceral leishmaniasis (VL) and human immunodeficiency v

194 Little is known about CD8 T cells in human visceral leishmaniasis (VL) and it is unclear if these c

195 ds to analyze longitudinal incidence data on visceral leishmaniasis (VL) and its sequela, post-kala-a

196 another promising preclinical candidate for visceral leishmaniasis (VL) and, in combination with ben

197 +) T cell effector responses during clinical visceral leishmaniasis (VL) are associated with elevated

198 Tests for visceral leishmaniasis (VL) are not uniformly effective

199 emic spread of Leishmania parasites in human visceral leishmaniasis (VL) are not well understood.

200 -27/TCCR pathway in the host defense against visceral leishmaniasis (VL) by monitoring the course of

201 When PBMCs from healed visceral leishmaniasis (VL) cases were infected with cGL

202 No vaccine is currently available for visceral leishmaniasis (VL) caused by Leishmania donovan

203 miR-21 in regulating immune responses during visceral leishmaniasis (VL) caused by Leishmania donovan

204 Control of visceral leishmaniasis (VL) caused by Leishmania donovan

205 l ibrutinib as a host-targeted treatment for visceral leishmaniasis (VL) caused by Leishmania donovan

206 eport a detrimental role of Ly6C(hi) iMOs in visceral leishmaniasis (VL) caused by Leishmania donovan

207 is also a vaccine antigen candidate against visceral leishmaniasis (VL) caused by Leishmania infantu

208 A periurban outbreak of visceral leishmaniasis (VL) caused by the protozoan Leis

209 Visceral leishmaniasis (VL) causes significant mortality

210 immunodeficiency virus (PWH) with recurrent visceral leishmaniasis (VL) could potentially drive Leis

211 The neglected tropical disease (NTD) visceral leishmaniasis (VL) has been targeted by the WHO

212 , sodium stibogluconate) in the treatment of visceral leishmaniasis (VL) has fallen from more than 85

213 r residual spraying (IRS) is used to control visceral leishmaniasis (VL) in India, but it is poorly q

214 ne had demonstrated very good cure rates for visceral leishmaniasis (VL) in India, Nepal, and Banglad

215 Visceral leishmaniasis (VL) in patients with human immun

216 s study was to identify the risk factors for visceral leishmaniasis (VL) in renal transplant recipien

217 Incidence of visceral leishmaniasis (VL) in the Indian subcontinent (

218 with human immunodeficiency virus (HIV) and visceral leishmaniasis (VL) in the VL-endemic areas of B

219 On the Indian subcontinent, visceral leishmaniasis (VL) incidence is on track to rea

220 sed approach to identify infected cells in a visceral leishmaniasis (VL) infection, which revealed pa

221 Visceral leishmaniasis (VL) is a debilitating human path

222 Visceral leishmaniasis (VL) is a fatal disease of the in

223 Visceral leishmaniasis (VL) is a form of leishmaniasis,

224 Visceral leishmaniasis (VL) is a life-threatening diseas

225 Visceral leishmaniasis (VL) is a parasitic disease endem

226 Visceral leishmaniasis (VL) is a parasitic infection tha

227 Visceral leishmaniasis (VL) is a potentially fatal paras

228 Visceral leishmaniasis (VL) is a serious and fatal disea

229 Visceral leishmaniasis (VL) is a serious parasitic disea

230 Mediterranean type of visceral leishmaniasis (VL) is a zoonotic parasitic infe

231 Visceral leishmaniasis (VL) is associated with severe im

232 Visceral leishmaniasis (VL) is caused by Leishmania dono

233 Active human visceral leishmaniasis (VL) is characterized by a progre

234 type 1 (Th1) and 17 (Th17) responses during visceral leishmaniasis (VL) is still unknown.

235 Visceral leishmaniasis (VL) is transmitted by sand flies

236 Control of visceral leishmaniasis (VL) on the Indian subcontinent h

237 Control of visceral leishmaniasis (VL) on the Indian subcontinent r

238 high miltefosine treatment failure rates for visceral leishmaniasis (VL) on the Indian subcontinent.

239 a dermal form of the disease, occurs in some visceral leishmaniasis (VL) patients following treatment

240 for the detection of Leishmania parasites in visceral leishmaniasis (VL) patients.

241 India is transitioning to the visceral leishmaniasis (VL) post-elimination phase where

242 Visceral leishmaniasis (VL) remains a major public healt

243 shmania parasites is critical for evaluating visceral leishmaniasis (VL) treatment response at an ear

244 ns of people across the world, in particular visceral leishmaniasis (VL) which is fatal unless treate

245 Since the early 1980s, visceral leishmaniasis (VL) which is, in general, a rura

246 ficant number of individuals may progress to visceral leishmaniasis (VL), a deadly disease that threa

247 No licensed vaccine exists against visceral leishmaniasis (VL), a disease caused by the Lei

248 ere is an urgent need for new treatments for visceral leishmaniasis (VL), a parasitic infection which

249 percentage of people who have been cured of visceral leishmaniasis (VL), and it contributes to trans

250 KDL) are usually extrapolated from those for visceral leishmaniasis (VL), but drug pharmacokinetics (

251 Visceral leishmaniasis (VL), caused by the Leishmania do

252 Visceral leishmaniasis (VL), caused by the protozoan par

253 leishmaniasis (PKDL), a cutaneous sequela of visceral leishmaniasis (VL), develops in some patients a

254 Visceral leishmaniasis (VL), due to Leishmania infantum,

255 shmania donovani (LD), responsible for fatal visceral leishmaniasis (VL), faces increasing challenges

256 is (PKDL), a heterogeneous dermal sequela of visceral leishmaniasis (VL), is challenging in terms of

257 diseases tegumentary leishmaniasis (TL) and visceral leishmaniasis (VL), is comparatively less well

258 Miltefosine (MIL), the only oral drug for visceral leishmaniasis (VL), is currently the first-line

259 te Leishmania donovani, a causative agent of visceral leishmaniasis (VL), require a potent host proin

260 In Tbilisi, Georgia, an endemic area for visceral leishmaniasis (VL), sand flies are abundant for

261 During visceral leishmaniasis (VL), Th1-based inflammation is i

262 In murine models of visceral leishmaniasis (VL), the parasitization of resid

263 Leishmania donovani causes visceral leishmaniasis (VL), the second most deadly vect

264 velopment of new oral treatment regimens for visceral leishmaniasis (VL), there is a need for early m

265 to infection with L. donovani, the cause of visceral leishmaniasis (VL), was determined by Northern

266 In an area endemic with Indian visceral leishmaniasis (VL), we performed direct xenodia

267 oral drug available for treatment of Indian visceral leishmaniasis (VL), which was shown to have an

268 ent years to be highly efficient in treating visceral leishmaniasis (VL)-the life-threatening form of

269 Poor access to diagnosis stymies control of visceral leishmaniasis (VL).

270 lie many of the immunologic defects in human visceral leishmaniasis (VL).

271 vani suggests that vaccination could prevent visceral leishmaniasis (VL).

272 FN-gamma) are critical for the resolution of visceral leishmaniasis (VL).

273 ntileishmanial efficacy against experimental visceral leishmaniasis (VL).

274 le utility against the kinetoplastid disease visceral leishmaniasis (VL).

275 recently approved for treatment of the fatal visceral leishmaniasis (VL).

276 t infects professional phagocytes and causes visceral leishmaniasis (VL).

277 potential first-in-class drug candidate for visceral leishmaniasis (VL).

278 nd cost-effective drugs for the treatment of visceral leishmaniasis (VL).

279 l C1 protein) and specific antibodies of the visceral leishmaniasis (VL).

280 mplications are sequelae of canine and human visceral leishmaniasis (VL).

281 no effective vaccine is available for human visceral leishmaniasis(VL) caused by Leishmania donovani

282 nsor construction, canine serum positive for visceral leishmaniasis was added to its surface and show

283 No patient with visceral leishmaniasis was found to be infectious by mic

284 To identify susceptibility loci for visceral leishmaniasis, we undertook genome-wide associa

285 enylphosphonium bromide] in a mouse model of visceral leishmaniasis were established.

286 treatment of the neglected tropical disease visceral leishmaniasis, were identified in a phenotypic

287 245/DDD01305143, a preclinical candidate for visceral leishmaniasis which acted through inhibition of

288 nly orally bioavailable drug for the disease visceral leishmaniasis, which is caused by the protozoan

289 n African trypanosomiasis, Buruli ulcer, and visceral leishmaniasis, which relies on intensified dise

290 gnificant risk factor for the development of visceral leishmaniasis, which results from skin inoculat

291 ic test is the primary diagnostic method for visceral leishmaniasis, while cutaneous leishmaniasis is